CervoMed publishes peer-reviewed data supporting neflamapimod for dementia
CervoMed announced peer-reviewed studies supporting neflamapimod as a DLB treatment. Positive trial biomarkers reinforce the drug's mechanism and rationalize further clinical development.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed